Cocrystal Pharma Advances Norovirus Antiviral with Phase 1b Trial
Event summary
- Cocrystal Pharma's Phase 1b norovirus challenge study for CDI-988 is underway at Emory University School of Medicine.
- CDI-988 is the first oral antiviral candidate targeting a highly conserved region of the viral 3CL protease in noroviruses.
- 2025 net loss narrowed to $8.8 million from $17.5 million in 2024, with R&D expenses decreasing to $5.1 million.
- Company received a $500,000 NIH grant for developing a broad-spectrum influenza A/B polymerase complex inhibitor.
The big picture
Cocrystal Pharma is addressing a significant unmet need in norovirus treatment, an area with no approved therapies and a $60 billion global economic burden. The company's structure-based drug discovery platform aims to create broad-spectrum antivirals that maintain efficacy despite viral mutations, positioning it competitively in the antiviral therapeutics market.
What we're watching
- Clinical Progress
- Whether CDI-988 demonstrates efficacy in reducing norovirus symptoms and viral shedding in the Phase 1b trial.
- Financial Sustainability
- The pace at which Cocrystal can extend its cash runway amid reduced R&D spending.
- Pipeline Expansion
- How the NIH grant will accelerate development of the influenza A/B polymerase complex inhibitor.
Our editorial coverage:
Related topics